Q-omics provides the consensus-scored PWWP2A profile across patient tissues and cancer cell-line models. PWWP2A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, PWWP2A is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, PWWP2A RNA expression shows 21,055 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KIRC as cancer lineages where PWWP2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PWWP2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PWWP2A survival associations across molecular data types. PWWP2A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PWWP2A RNA expression–survival associations across cancer types. High PWWP2A expression shows unfavorable associations in UVM, KICH, LIHC, KIRP and LGG, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for PWWP2A RNA expression.
This table summarizes PWWP2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PWWP2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PWWP2A shows higher tumor expression in KIRC, LIHC, HNSC, BRCA, STAD and CHOL. The KIRC box plot shows higher PWWP2A RNA expression in tumor versus normal tissue (log2 FC = +0.750, t-test p < 0.001).
This table shows molecular features associated with PWWP2A in patient tissues and cancer cell lines. In patient samples, PWWP2A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PWWP2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
